Literature DB >> 25547388

The biology of castration-resistant prostate cancer.

Fei Lian, Nitya V Sharma, Josue D Moran, Carlos S Moreno.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25547388      PMCID： PMC4314372          DOI： 10.1016/j.currproblcancer.2014.11.004

Source DB:  PubMed          Journal:  Curr Probl Cancer        ISSN： 0147-0272            Impact factor:   3.187


× No keyword cloud information.
  139 in total

Review 1.  Challenges and recommendations for early identification of metastatic disease in prostate cancer.

Authors:  E David Crawford; Nelson N Stone; Evan Y Yu; Phillip J Koo; Stephen J Freedland; Susan F Slovin; Leonard G Gomella; E Roy Berger; Thomas E Keane; Paul Sieber; Neal D Shore; Daniel P Petrylak
Journal:  Urology       Date:  2014-01-08       Impact factor: 2.649

2.  Efficacy of cetuximab in metastatic castration-resistant prostate cancer might depend on EGFR and PTEN expression: results from a phase II trial (SAKK 08/07).

Authors:  Richard Cathomas; Christian Rothermundt; Dirk Klingbiel; Lukas Bubendorf; Rolf Jaggi; Daniel C Betticher; Peter Brauchli; Denise Cotting; Cornelia Droege; Ralph Winterhalder; Daniele Siciliano; Dominik R Berthold; Miklos Pless; Ralph Schiess; Roger von Moos; Silke Gillessen
Journal:  Clin Cancer Res       Date:  2012-09-12       Impact factor: 12.531

3.  Molecular alterations of EGFR and PTEN in prostate cancer: association with high-grade and advanced-stage carcinomas.

Authors:  Silvia de Muga; Silvia Hernández; Laia Agell; Marta Salido; Nuria Juanpere; Marta Lorenzo; José A Lorente; Sergio Serrano; Josep Lloreta
Journal:  Mod Pathol       Date:  2010-03-05       Impact factor: 7.842

4.  Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer.

Authors:  Irfan A Asangani; Vijaya L Dommeti; Xiaoju Wang; Rohit Malik; Marcin Cieslik; Rendong Yang; June Escara-Wilke; Kari Wilder-Romans; Sudheer Dhanireddy; Carl Engelke; Mathew K Iyer; Xiaojun Jing; Yi-Mi Wu; Xuhong Cao; Zhaohui S Qin; Shaomeng Wang; Felix Y Feng; Arul M Chinnaiyan
Journal:  Nature       Date:  2014-04-23       Impact factor: 49.962

5.  Selective inhibition of tumor oncogenes by disruption of super-enhancers.

Authors:  Jakob Lovén; Heather A Hoke; Charles Y Lin; Ashley Lau; David A Orlando; Christopher R Vakoc; James E Bradner; Tong Ihn Lee; Richard A Young
Journal:  Cell       Date:  2013-04-11       Impact factor: 41.582

6.  Evaluation of urinary prostate cancer antigen-3 (PCA3) and TMPRSS2-ERG score changes when starting androgen-deprivation therapy with triptorelin 6-month formulation in patients with locally advanced and metastatic prostate cancer.

Authors:  Luis Martínez-Piñeiro; Jack A Schalken; Patrick Cabri; Pascal Maisonobe; Alexandre de la Taille
Journal:  BJU Int       Date:  2014-04-04       Impact factor: 5.588

7.  Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer.

Authors:  Qianben Wang; Wei Li; Yong Zhang; Xin Yuan; Kexin Xu; Jindan Yu; Zhong Chen; Rameen Beroukhim; Hongyun Wang; Mathieu Lupien; Tao Wu; Meredith M Regan; Clifford A Meyer; Jason S Carroll; Arjun Kumar Manrai; Olli A Jänne; Steven P Balk; Rohit Mehra; Bo Han; Arul M Chinnaiyan; Mark A Rubin; Lawrence True; Michelangelo Fiorentino; Christopher Fiore; Massimo Loda; Philip W Kantoff; X Shirley Liu; Myles Brown
Journal:  Cell       Date:  2009-07-23       Impact factor: 41.582

8.  Phase II trial of RAD001 and bicalutamide for castration-resistant prostate cancer.

Authors:  Mari Nakabayashi; Lilian Werner; Kevin D Courtney; Geoffrey Buckle; William K Oh; Glen J Bubley; Julia H Hayes; Douglas Weckstein; Aymen Elfiky; Danny M Sims; Philip W Kantoff; Mary-Ellen Taplin
Journal:  BJU Int       Date:  2012-08-29       Impact factor: 5.588

Review 9.  Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches.

Authors:  T Karantanos; P G Corn; T C Thompson
Journal:  Oncogene       Date:  2013-06-10       Impact factor: 9.867

10.  The genomic complexity of primary human prostate cancer.

Authors:  Michael F Berger; Michael S Lawrence; Francesca Demichelis; Yotam Drier; Kristian Cibulskis; Andrey Y Sivachenko; Andrea Sboner; Raquel Esgueva; Dorothee Pflueger; Carrie Sougnez; Robert Onofrio; Scott L Carter; Kyung Park; Lukas Habegger; Lauren Ambrogio; Timothy Fennell; Melissa Parkin; Gordon Saksena; Douglas Voet; Alex H Ramos; Trevor J Pugh; Jane Wilkinson; Sheila Fisher; Wendy Winckler; Scott Mahan; Kristin Ardlie; Jennifer Baldwin; Jonathan W Simons; Naoki Kitabayashi; Theresa Y MacDonald; Philip W Kantoff; Lynda Chin; Stacey B Gabriel; Mark B Gerstein; Todd R Golub; Matthew Meyerson; Ashutosh Tewari; Eric S Lander; Gad Getz; Mark A Rubin; Levi A Garraway
Journal:  Nature       Date:  2011-02-10       Impact factor: 49.962
View more
  8 in total

1.  Two calix[4]pyrroles as potential therapeutics for castration-resistant prostate cancer.

Authors:  Imene Ben Toumia; Marco Ponassi; Paola Barboro; Erika Iervasi; Gabriela Coronel Vargas; Barbara Banelli; Stefano Fiordoro; Leila Chekir Ghedira; Franz Heinrich Kohnke; Alberto Izzotti; Camillo Rosano
Journal:  Invest New Drugs       Date:  2022-08-17       Impact factor: 3.651

Review 2.  Oxidative stress and redox signaling in CRPC progression: therapeutic potential of clinically-tested Nrf2-activators.

Authors:  Debasis Mondal; Devin Narwani; Shahnawaz Notta; Dawood Ghaffar; Nikhil Mardhekar; Syed S A Quadri
Journal:  Cancer Drug Resist       Date:  2021-03-19

3.  Registered report: the androgen receptor induces a distinct transcriptional program in castration-resistant prostate cancer in man.

Authors:  Denise Chronscinski; Srujana Cherukeri; Fraser Tan; Nicole Perfito; Joelle Lomax; Elizabeth Iorns
Journal:  PeerJ       Date:  2015-09-15       Impact factor: 2.984

Review 4.  Diagnostic, prognostic and predictive value of cell-free miRNAs in prostate cancer: a systematic review.

Authors:  Edgars Endzeliņš; Vita Melne; Zane Kalniņa; Vilnis Lietuvietis; Una Riekstiņa; Alicia Llorente; Aija Linē
Journal:  Mol Cancer       Date:  2016-05-18       Impact factor: 27.401

5.  Selection and characterization of DNA aptamer for metastatic prostate cancer recognition and tissue imaging.

Authors:  Minlan Duan; Yuqian Long; Cai Yang; Xiaoqiu Wu; Yang Sun; Jianglin Li; Xiaoxiao Hu; Wei Lin; Dongmei Han; Yifan Zhao; Jing Liu; Mao Ye; Weihong Tan
Journal:  Oncotarget       Date:  2016-06-14

Review 6.  Molecular and cellular mechanisms of castration resistant prostate cancer.

Authors:  Yiqiao Huang; Xianhan Jiang; Xue Liang; Ganggang Jiang
Journal:  Oncol Lett       Date:  2018-02-27       Impact factor: 2.967

7.  The JNK inhibitor AS602801 Synergizes with Enzalutamide to Kill Prostate Cancer Cells In Vitro and In Vivo and Inhibit Androgen Receptor Expression.

Authors:  Zhenghong Li; Carrie Sun; Sijia Tao; Adeboye O Osunkoya; Rebecca S Arnold; John A Petros; Xiongbing Zu; Carlos S Moreno
Journal:  Transl Oncol       Date:  2020-03-18       Impact factor: 4.243

8.  Efficacy of docetaxel combined carboplatin for the treatment of patients with castration-resistant prostate cancer: A protocol of systematic review and meta-analysis.

Authors:  Chun-Lin Pu; Jiu-Zhi Li; Wen-Long Fan
Journal:  Medicine (Baltimore)       Date:  2020-05-22       Impact factor: 1.817
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.